Your browser doesn't support javascript.
loading
Rapid development of an inactivated vaccine for SARS-CoV-2
Qiang Gao; Linlin Bao; Haiyan Mao; Lin Wang; Kangwei Xu; minnan Yang; Yajing Li; Ling Zhu; Nan Wang; Zhe Lv; Hong Gao; Xiaoqin Ge; Biao Kan; Yaling Hu; Jiangning Liu; Fang Cai; Deyu Jiang; Yanhui Yin; Chengfeng Qin; Jing Li; Xuejie Gong; Xiuyu Lou; Wen Shi; Dongdong Wu; Hengming Zhang; Lang Zhu; Wei Deng; Yurong Li; Jinxing Lu; Changgui Li; Xiangxi Wang; Weidong Yin; Yanjun Zhang; Chuan Qin.
Affiliation
  • Qiang Gao; Sinovac Biotech Ltd
  • Linlin Bao; Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College
  • Haiyan Mao; Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention
  • Lin Wang; Sinovac Biotech Ltd
  • Kangwei Xu; Division of Respiratory Virus Vaccines, National Institute for Food and Drug Control
  • minnan Yang; Institute of Biophysics, Chinese Academy of Sciences
  • Yajing Li; Sinovac Biotech Ltd
  • Ling Zhu; Institute of Biophysics, Chinese Academy of Sciences
  • Nan Wang; Institute of Biophysics, Chinese Academy of Sciences
  • Zhe Lv; Institute of Biophysics, Chinese Academy of Sciences
  • Hong Gao; Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College
  • Xiaoqin Ge; Sinovac Biotech Ltd
  • Biao Kan; National Institute for Communicable Disease Control and Prevention, China CDC
  • Yaling Hu; Sinovac Biotech Ltd
  • Jiangning Liu; Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College
  • Fang Cai; Sinovac Biotech Ltd
  • Deyu Jiang; Sinovac Biotech Ltd
  • Yanhui Yin; Sinovac Biotech Ltd
  • Chengfeng Qin; Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences
  • Jing Li; Sinovac Biotech Ltd
  • Xuejie Gong; Sinovac Biotech Ltd
  • Xiuyu Lou; Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention
  • Wen Shi; Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention
  • Dongdong Wu; Sinovac Biotech Ltd
  • Hengming Zhang; Sinovac Biotech Ltd
  • Lang Zhu; Sinovac Biotech Ltd
  • Wei Deng; Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College
  • Yurong Li; Sinovac Biotech Ltd
  • Jinxing Lu; National Institute for Communicable Diseases
  • Changgui Li; Division of Respiratory Virus Vaccines, National Institute for Food and Drug Control
  • Xiangxi Wang; Institute of Biophysics, Chinese Academy of Sciences
  • Weidong Yin; Sinovac Biotech Ltd
  • Yanjun Zhang; Zhejiang Center for Disease Control and Prevention
  • Chuan Qin; Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences
Preprint in English | bioRxiv | ID: ppbiorxiv-046375
ABSTRACT
The COVID-19 pandemic caused by SARS-CoV-2 has brought about an unprecedented crisis, taking a heavy toll on human health, lives as well as the global economy. There are no SARS-CoV-2-specific treatments or vaccines available due to the novelty of this virus. Hence, rapid development of effective vaccines against SARS-CoV-2 is urgently needed. Here we developed a pilot-scale production of a purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc), which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats and non-human primates. These antibodies potently neutralized 10 representative SARS-CoV-2 strains, indicative of a possible broader neutralizing ability against SARS-CoV-2 strains circulating worldwide. Immunization with two different doses (3g or 6 g per dose) provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without any antibody-dependent enhancement of infection. Systematic evaluation of PiCoVacc via monitoring clinical signs, hematological and biochemical index, and histophathological analysis in macaques suggests that it is safe. These data support the rapid clinical development of SARS-CoV-2 vaccines for humans. One Sentence SummaryA purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc) confers complete protection in non-human primates against SARS-CoV-2 strains circulating worldwide by eliciting potent humoral responses devoid of immunopathology
License
cc_by_nc_nd
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: Available Collection: Preprints Database: bioRxiv Type of study: Experimental_studies / Prognostic study / Systematic review Language: English Year: 2020 Document type: Preprint
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: Available Collection: Preprints Database: bioRxiv Type of study: Experimental_studies / Prognostic study / Systematic review Language: English Year: 2020 Document type: Preprint